


PHARMACEUTICAL 2021

## AILERON THERAPEUTICS INC Rank 292 of 402







PHARMACEUTICAL 2021

AILERON THERAPEUTICS INC Rank 292 of 402

The relative strengths and weaknesses of AILERON THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AILERON THERAPEUTICS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 27% points. The greatest weakness of AILERON THERAPEUTICS INC is the variable Net Income, reducing the Economic Capital Ratio by 122% points.

The company's Economic Capital Ratio, given in the ranking table, is -2.4%, being 50% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	16,326
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,960
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-9.0
Other Expenses	0
Other Liabilities	219
Other Net Income	-661
Other Revenues	0
Property and Equipment	15
Research and Development	11,166
Selling, General and Administrative Expense	9,330

Output Variable	Value in 1000 USD
Assets	16,341
Liabilities	4,179
Expenses	20,496
Revenues	0
Stockholders Equity	12,162
Net Income	-21,157
Comprehensive Net Income	-21,162
Economic Capital Ratio	-2.4%

